Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity

Proceedings of the National Academy of Sciences(2021)10.1073/pnas.2107424118Source: DataRank Database

Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity is a research paper published in Proceedings of the National Academy of Sciences (2021). On theSindex it has a DataRank of 0.778. It has been cited 178 times.

N/A

0.778DataRank · unranked

Scored on demand from live citation data

178 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 8.37)OA: greenTopics (32)Linked Datasets (10)DataCite Reuse (10)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (0/2)

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.778

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (4)

Polina Weitzenfeld ORCID,Patrick Smith ORCID,Jeffrey V. Ravetch ORCID,Itziar Ibarlucea-Benitez ORCID

Live enrichment

PubMed:34155121 OpenAlex:https://openalex.org/W3174289113

HHS | NIH | National Cancer Institute

Grant: R35CA196620

HHS | NIH | National Cancer Institute

Grant: R01CA244327

The Kimberly Lawrence-Netter Cancer Research Discovery Fund

Grant: N/A

FWCI

8.37

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: https://www.pnas.org/site/aboutpnas/licenses.xhtml

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8256000

publisherhttp://www.pnas.org/syndication/doi/10.1073/pnas.2107424118

publisherhttps://pnas.org/doi/pdf/10.1073/pnas.2107424118

journalhttps://doi.org/10.1073/pnas.2107424118

Fields of Study

Immunotherapy and Immune ResponsesGlycosylation and Glycoproteins ResearchChemokine receptors and signaling

MeSH Terms

Immune Checkpoint InhibitorsAnimalsAntibodiesHumansImmunityMice, Inbred C57BLModels, BiologicalNeoplasmsPhenotypeAntigens, CDMice, KnockoutDisease ProgressionCell Line, TumorCell ProliferationMiceTumor MicroenvironmentSialic Acid Binding Immunoglobulin-like Lectins

Keywords

SIGLECImmunotherapyIn vivoImmune systemImmunityMyeloidCancer researchBlockadeImmunologyImmune checkpointBiologyReceptor

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 5 of Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity

10.6084/m9.figshare.21443558.v1figshare

Additional file 1 of Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity

10.6084/m9.figshare.21443546figshare

Additional file 2 of Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity

10.6084/m9.figshare.21443549.v1figshare

Additional file 2 of Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity

10.6084/m9.figshare.21443549figshare

Additional file 3 of Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity

10.6084/m9.figshare.21443552.v1figshare

Additional file 4 of Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity

10.6084/m9.figshare.21443555figshare

Additional file 3 of Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity

10.6084/m9.figshare.21443552figshare

Additional file 4 of Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity

10.6084/m9.figshare.21443555.v1figshare

Additional file 1 of Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity

10.6084/m9.figshare.21443546.v1figshare

Additional file 5 of Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity

10.6084/m9.figshare.21443558figshare

Related Papers (9)

Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation

N/A

0.771DataRank · unranked

Communications Biology(2020)

co-cited

10.1038/s42003-020-0845-0

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

N/A

4.8DataRank · unranked

Nature Medicine(2021)

co-cited

10.1038/s41591-021-01436-0

The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans

N/A

0.934DataRank · unranked

Nature Reviews Drug Discovery(2021)

co-cited

10.1038/s41573-020-00093-1

Modulation of Siglec-7 Signaling Via In Situ-Created High-Affinity cis-Ligands

ACS Central Science(2021)

co-cited

10.1021/acscentsci.1c00064

Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia

N/A

0.483DataRank · unranked

Leukemia(2021)

co-cited

10.1038/s41375-021-01188-3

Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia

N/A

0.474DataRank · unranked

Journal for ImmunoTherapy of Cancer(2022)

co-cited

10.1136/jitc-2022-004850

Antibody-Mediated LILRB2-Receptor Antagonism Induces Human Myeloid-Derived Suppressor Cells to Kill Mycobacterium tuberculosis

Frontiers in Immunology(2022)

co-cited

10.3389/fimmu.2022.865503

A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML

N/A

0.875DataRank · unranked

Blood(2023)

co-cited

10.1182/blood.2023021054

Alemtuzumab in relapsed immune severe aplastic anemia: Long‐term results of a phase II study

N/A

0.490DataRank · unranked

American Journal of Hematology(2023)

co-cited

10.1002/ajh.26924

Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity

FAIR Checklist

DataRank Breakdown

Authors (4)

Funding (3 grants)

Impact

Open Access

Topics

Linked Datasets (10)

Related Papers (9)